On a drizzly, cold February afternoon, Lilly Pinchin is at ease surrounded by an entourage of animals in her family’s ...

Young rider opens up on how condition affects her daily life, leaving school at 15 and the ‘peace’ she feels when racing ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

We recently published a list of the 12 Best Long-Term Growth Stocks to Buy Now. In this article, we are going to take a look ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...

There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

In a report released today, Geoff Meacham from Citi maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s shares ...

NEW YORK : The S&P 500 and the Nasdaq ended higher, while the Dow closed lower after a choppy trading session on Thursday, as ...

Eli Lilly (LLY) reported in-line fourth-quarter sales on Thursday, while reiterating a 2025 revenue guidance that implies the top line will grow at the same pace as it did last year. Revenue climbed ...

Eli Lilly And Co. (LLY) reported earnings for its fourth quarter that increased from last year and beat the Street estimates. The ...

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...